Table 3.
Outcomes of published phase III studies in elderly patients with MM
| Regimen [reference] | Maintenance? | n | PR (%) | CR (%) | Median PFS (months) | Median OS (months) | 3‐year OS (%) |
|---|---|---|---|---|---|---|---|
| MP 4 | No | 196 | 35 | 2 | 17.8 | 33.2 | – |
| MP 10 | No | 179 | 40 | 4 | 14 | 32 | – |
| MP 13 | No | 173 | 45 | NR | 11 | 31 | – |
| MP 6, 14 | No | 164 | 47.6 | 3.7 | 14.5 | 47.6 | – |
| MP 15 | No | 116 | 31 | 1 | 18.5 | 29.1 | – |
| MPT 16 | Yes | 184 | 57 | 13 | 15 | 29 | – |
| MPT 13 | Yes | 171 | 66 | NR | 15 | 40 | – |
| MPT 6, 14 | Yes | 167 | 76 | 15.6 | 21.8 | 45 | – |
| MPT 4 | No | 125 | 76 | 13 | 27.5 | 51.6 | – |
| MPT 15 | No | 113 | 62 | 7 | 24.1 | 44 | – |
| MPV 17 | Yes | 167 | 73 | 34 | NRb | – | NRb |
| MPV 18, 24 | Yes | 130 | 80 | 20 | 32 | – | 74 |
| MPV 19, 20 | No | 344 | 71 | 30 | 24 | – | 68.5 |
| MPV 21 | No | 257 | 81 | 24 | a | – | 87 |
| VTP 18 | Yes | 130 | 81 | 28 | 25 | – | 65 |
| VD 17 | Yes | 168 | 71 | 31 | NRb | – | NRb |
| VTD 17 | Yes | 167 | 79 | 38 | NRb | – | NRb |
| RD 8 | Yes | 121 | – | – | 25.5 | NRc | 58d |
PR, partial remission; CR, complete remission; Med. PFS, median progression‐free survival (months); Med. OS, median overall survival (months); 3‐yr OS, three‐year overall survival (%); MP, melphalan, prednisone; VD, bortezomib, dexamethasone; RD, lenalidomide, dexamethasone; MPT, melphalan, prednisone, thalidomide; MPV, melphalan, prednisone, bortezomib; VTP, bortezomib, thalidomide, prednisone; VTD, bortezomib, thalidomide, dexamethasone.
a
Three‐year PFS = 41%.
b
At 49 weeks.
c
At 37 weeks.
d
Four‐year OS.